CHRISTOPHER STOCK, B.A.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In a recent letter Kinzie and Taylor (1) discuss their rationale for recommending the prophylactic use of folinic acid for patients receiving high doses of trimethoprim-sulfamethoxazole. Although there are legitimate concerns about hematologic toxicity from high doses of trimethoprim-sulfamethoxazole, I have reservations about the routine use of folinic acid. To date there are no well-designed studies with trimethoprim-sulfamethoxazole or other antifolates that compare treatment outcomes when using or omitting folinic acid.
The inference that Pneumocystis carinii, the frequent target of high-dose trimethoprim-sulfamethoxazole, cannot utilize exogenous folinic acid is probably correct as it is generally thought that protozoa
STOCK C. Trimethoprim-Sulfamethoxazole and Folinic Acid. Ann Intern Med. 1985;102:277. doi: 10.7326/0003-4819-102-2-277_1
Download citation file:
Published: Ann Intern Med. 1985;102(2):277.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use